As GLP-1 supply stabilizes, compounders face uncertain future

Image credit: haberdoedas via Unsplash

The recent shortage of GLP-1 drugs like semaglutide and tirzepatide, widely used for weight loss and diabetes management, led many patients to turn to compounded alternatives. FDA regulations allow compounding when commercially approved drugs are in short supply, and these customized formulations, made by prescription and containing the same active ingredients, quickly gained popularity. Despite some concerns raised about their safety, demand for compounded GLP-1 medications surged as patients sought accessible options. Now that commercial supply is returning to normal, attention is shifting to how the FDA will regulate this space and whether compounded options will remain available in the long term.

Source

Mattingly TJ, Conti RM. Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists. JAMA Health Forum. 2025;6(1):e245015. doi:10.1001/jamahealthforum.2024.5015

Additional Reading

https://www.pharmaceutical-technology.com/features/the-glp-1-drug-shortage-is-over-whats-next-for-the-compounders/

https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

https://finance.yahoo.com/news/glp-1-drug-shortage-over-143913812.html